Recordati Industria Chimica e Farmaceutica S.p.A(RER1) News

Date	Title
Mar 3	3 European Stocks Estimated To Be Undervalued In March 2025
Feb 13	RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS